Information  X 
Enter a valid email address

Brenntag AG (BNR)

  Print      Mail a friend       Annual reports

Wednesday 06 March, 2019

Brenntag AG

S. Holland to retire as CEO by Feb. 2020

RNS Number : 0045S
Brenntag AG
06 March 2019

Brenntag AG / Key word(s): Personnel
Brenntag AG: Steven Holland to retire as CEO by February 2020 at the end of his contract 

06-March-2019 / 07:31 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Steven Holland, CEO of Brenntag AG, informed the chairman of the Supervisory Board today that he has decided he will retire after nine years as CEO when his current contract ends in February 2020 and he will not be available for an extension of his contract. He remains fully committed throughout the transition period. Stefan Zuschke, the chairman of the Supervisory Board, points out the significant contribution by Steven Holland in Brenntag's journey from private to public ownership and its expansion into a truly global chemical distribution company and market leader. A decision on succession will be made by the Supervisory Board based on a structured selection process.
Brenntag AG
Thomas Langer, VP Corporate Finance & Investor Relations
Phone: +49 201 6496 1496
Fax: +49 201 6496 2003
eMail: [email protected]

End of ad hoc announcement


06-March-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. 
Archive at






Brenntag AG

Messeallee 11

45131 Essen



+49 (0) 201 6496 0


+49 (0) 201 6496 1010


[email protected]









Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange



End of Announcement

DGAP News Service


784319  06-March-2019 CET/CEST

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

a d v e r t i s e m e n t